Formulation and Evaluation of Nanosuspension of Ranolazine

Objectives The main objective of the study was to formulate and evaluate Ranolazine nanosuspension. Ranolazine is an oral anginal medication that belongs to Biopharmaceutics Classification System BCS Class II with low solubility and enters hepatic circulation.Methods Nanoedge technology was used to prepare the Ranolazine nanosuspension. Various characterization studies including drug content yield Fourier Transform Infrared Spectroscopy FT-IR Differential Scanning Calorimetry DSC Scanning electron microscopy SEM and in vitro drug release were carried out. HPMC E15 Eudragit L100 were used as stearic stabilizers lecithin as an electrostatic stabilizer Tween 80 as a surfactant ethanol as the solvent and water as the antisolvent.Result Based on the dissolution study the F3 formulation containing HPMC E15 as the stabilizer was considered the ideal formulation exhibiting a maximum drug release of 84.02 at 60 minutes.Conclusion FTIR and DSC studies indicated good compatibility within the dispersion.